| UHC Commercial Medical & Drug | Exondys 51® (Eteplirsen) – Commercial Medical Benefit Drug Policy | 2025-07-01 |
| UHC Commercial Medical & Drug | Gonadotropin Releasing Hormone Analogs – Commercial Medical Benefit Drug Policy | 2025-07-01 |
| UHC Commercial Medical & Drug | Korsuva® (Difelikefalin) – Commercial Medical Benefit Drug Policy | 2025-07-01 |
| UHC Commercial Medical & Drug | Niktimvo™ (Axatilimab-Csfr) – Commercial Medical Benefit Drug Policy | 2025-07-01 |
| UHC Commercial Medical & Drug | Provider Administered Drugs – Preferred Products – Commercial Medical Benefit Drug Policy | 2025-07-01 |
| UHC Commercial Medical & Drug | Saphnelo® (Anifrolumab-Fnia) – Commercial Medical Benefit Drug Policy | 2025-07-01 |
| UHC Commercial Medical & Drug | Scenesse® (Afamelanotide) – Commercial Medical Benefit Drug Policy | 2025-07-01 |
| UHC Commercial Medical & Drug | Spevigo® (Spesolimab-Sbzo) – Commercial Medical Benefit Drug Policy | 2025-07-01 |
| UHC Commercial Medical & Drug | Spevigo® (Spesolimab-Sbzo) – IV and Subcutaneous Formulations (for UHCWest Only) – Commercial Medical Benefit Drug Policy | 2025-07-01 |
| UHC Commercial Medical & Drug | Viltepso® (Viltolarsen) – Commercial Medical Benefit Drug Policy | 2025-07-01 |